EASD 2025: zimislecel infusion advances insulin independence in T1D
From a pharmaceutical strategy perspective, zimislecel could anchor a premium, disease-modifying segment in high-risk T1D.
Comment & Opinion
Top 20 biopharma market caps fall 5.7% amid industry challenges
Cystic fibrosis market forecast to reach $16.0bn by 2034 in the 7MM
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
Morocco’s sweeping pharmaceutical pricing reform
ESC 2025: Higher leg muscle scores reduce cardiovascular risk independent of BMI
Four drugs race for first bispecific ADC approval
2024 saw growth recovery for almost all top biopharma companies
